PDSB PDS Biotechnology Corp

Price (delayed)

$1.225

Market cap

$68.37M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.67

Enterprise value

$62.57M

?
Relative Growth: Rel. Growth: 15
Relative Strength: Rel. Strength: 70
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 5

PDS Biotech is a clinical-stage immunotherapy company with a growing pipeline of cancer immunotherapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology platform. Versamune® effectively ...

Highlights
PDS Biotechnology's EPS has increased by 29% YoY and by 9% QoQ
PDS Biotechnology's debt has decreased by 16% YoY and by 6% QoQ
The equity has plunged by 83% YoY and by 58% from the previous quarter
The quick ratio is down by 24% from the previous quarter and by 2.7% YoY

Key stats

What are the main financial stats of PDSB

PDSB stock price

How has the PDS Biotechnology stock price performed over time
Intraday
13.43%
1 week
14.49%
1 month
22.5%
1 year
-25.76%
YTD
59.13%
QTD
102.48%

Financial performance

How have PDS Biotechnology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$28.96M
Net income
-$33.36M
Gross margin
N/A
Net margin
N/A
The operating income has grown by 18% YoY and by 8% from the previous quarter
PDS Biotechnology's net income has increased by 6% YoY and by 3.3% from the previous quarter

Price vs fundamentals

How does PDSB's price correlate with its fundamentals

Growth

What is PDS Biotechnology's growth rate over time

Valuation

What is PDS Biotechnology stock price valuation
P/E
N/A
P/B
17.56
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
PDS Biotechnology's EPS has increased by 29% YoY and by 9% QoQ
The P/B is 187% higher than the last 4 quarters average of 5.4
The equity has plunged by 83% YoY and by 58% from the previous quarter

Efficiency

How efficient is PDS Biotechnology business performance
PDSB's ROE has shrunk by 130% YoY and by 43% QoQ
The ROA is down by 48% YoY and by 13% QoQ
PDS Biotechnology's ROIC has increased by 38% YoY and by 10% from the previous quarter

Dividends

What is PDSB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PDSB.

Financial health

How did PDS Biotechnology financials performed over time
PDS Biotechnology's total assets is 19% more than its total liabilities
PDS Biotechnology's total assets has decreased by 48% YoY and by 19% from the previous quarter
PDSB's current ratio is down by 24% since the previous quarter and by 3% year-on-year
The debt to equity has soared by 122% since the previous quarter
The equity has plunged by 83% YoY and by 58% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.